Neurovance is engaged in the development and commercialization of novel therapies for attention deficit hyperactivity disorders.
Business Model:
Revenue: $7M
Employees: 11-50
Neurovance was acquired by
Otsuka Pharmaceutical.
The acquisition happend on 2017-03-02.
Details of the transaction were not public
Address: 43 Thorndike St
City: Cambridge
State: MA
Zip: 02141
Country: US
Neurovance is engaged in the development and commercialization of novel therapies for attention deficit hyperactivity disorders.
Contact Phone:
+16177580300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2012 | Series A | $20M |
GBS Venture Partners Venture Investors |
2/2016 | Debt | $7.5M | 3/2015 | Series A | $5.5M | 6/2015 | Series A | 1 | $6.5M |
Venture Investors Venture Investors |
2/2012 | Venture Round | $478.1k | 12/2016 | Debt | $554.3k | 7/2016 | Debt Financing | $6M | 3/2012 | Equity | $478.1k |
GBS Venture Partners Venture Investors |
4/2014 | Series A | 7 | $6.3M |
GBS Ventures H&a;Q Healthcare Investors Novartis Venture Fund State of Wisconsin Investment Board Tekla Capital Management Timothy J. Barberich Venture Investors GBS Ventures H&a;Q Healthcare Investors Novartis Venture Fund State of Wisconsin Investment Board Tekla Capital Management Timothy J. Barberich Venture Investors |
10/2012 | Venture Round | 4 | $7M |
State of Wisconsin Investment Board GBS Ventures Novartis Venture Fund H&a;Q Healthcare Investors State of Wisconsin Investment Board GBS Ventures Novartis Venture Fund |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|